The Journal of Immunology, Vol 135, Issue 4 2374-2377, Copyright © 1985 by American Association of Immunologists

ARTICLES

Activation of tissue macrophages from AIDS patients: in vitro response of AIDS alveolar macrophages to lymphokines and interferon-gamma

HW Murray, RA Gellene, DM Libby, CD Rothermel and BY Rubin

To test the hypothesis that tissue macrophages from AIDS patients have no intrinsic defects in either antimicrobial activity or in the capacity to respond to T cell-derived activating stimuli, alveolar macrophages from 11 patients were treated with crude lymphokines produced by healthy donors. After 72 hr of pretreatment with 10% mitogen- or antigen-induced crude lymphokines (which contained 300 U/ml of interferon-gamma [IFN-gamma]), AIDS alveolar macrophages generated twofold to threefold more H2O2 and readily inhibited the replication of the intracellular pathogens Toxoplasma gondii and Chlamydia psittaci. These responses were indistinguishable from those displayed by activated alveolar cells from 12 non-AIDS patients and three healthy volunteers. As judged by the abrogating effects of a neutralizing anti- human IFN-gamma monoclonal antibody, lymphokine-induced alveolar macrophage activation appeared to be largely IFN-gamma-dependent; thus, macrophages were also stimulated with recombinant (r)IFN-gamma alone. Seventy-two hours of treatment with 300 U/ml of rIFN-gamma resulted in both enhanced oxidative and antimicrobial activity comparable to that achieved by crude lymphokines, and the responsiveness of AIDS alveolar macrophages to rIFN-gamma was identical to control cells. These in vitro results suggest that tissue mononuclear phagocytes from AIDS patients a) are free of apparent defects in intracellular antimicrobial activity, b) are fully responsive to activating T cell products, and c) support the use of IFN-gamma as a potential macrophage-activating immunotherapeutic agent in AIDS-related opportunistic infections.

This article has been cited by other articles:

				J. M. Beck The Immunocompromised Host: HIV Infection Proceedings of the ATS, December 1, 2005; 2(5): 423 - 427. [Abstract] [Full Text] [PDF]

				A.J. CANT, S.B. GORDON, R.C. READ, C.A. HART, and C. WINSTANLEY Respiratory infections: Proceedings of the Eighth Liverpool Tropical School Bayer Symposium of Microbial Disease held on 3 February 2001 J. Med. Microbiol., November 1, 2002; 51(11): 903 - 914. [Full Text] [PDF]

				J.-Y. Seo, S. Y. Seong, B.-Y. Ahn, I. C. Kwon, H. Chung, and S. Y. Jeong Cross-Protective Immunity of Mice Induced by Oral Immunization with Pneumococcal Surface Adhesin A Encapsulated in Microspheres Infect. Immun., March 1, 2002; 70(3): 1143 - 1149. [Abstract] [Full Text] [PDF]

				S B Gordon and R C Read Macrophage defences against respiratory tract infections: The immunology of childhood respiratory infections Br. Med. Bull., March 1, 2002; 61(1): 45 - 61. [Abstract] [Full Text] [PDF]

				W. J. Martin II and R. Pasula Role of Alveolar Macrophages in Host Defense against Pneumocystis carinii Am. J. Respir. Cell Mol. Biol., October 1, 2000; 23(4): 434 - 435. [Full Text]

				S.-Y. Seong, N.-H. Cho, I. C. Kwon, and S. Y. Jeong Protective Immunity of Microsphere-Based Mucosal Vaccines against Lethal Intranasal Challenge with Streptococcus pneumoniae Infect. Immun., July 1, 1999; 67(7): 3587 - 3592. [Abstract] [Full Text] [PDF]

				J. F. Downing, D. L. Kachel, R. Pasula, and W. J. Martin II Gamma Interferon Stimulates Rat Alveolar Macrophages To Kill Pneumocystis carinii by L-Arginine- and Tumor Necrosis Factor-Dependent Mechanisms Infect. Immun., March 1, 1999; 67(3): 1347 - 1352. [Abstract] [Full Text] [PDF]

				J. A. Fishman Prevention of Infection Due to Pneumocystis carinii Antimicrob. Agents Chemother., May 1, 1998; 42(5): 995 - 1004. [Full Text]